

Natali Pflug

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4260947/publications.pdf>

Version: 2024-02-01

13
papers

493
citations

1163117

8
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

889
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 49-62.	1.4	244
2	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. <i>Nature Communications</i> , 2018, 9, 697.	12.8	73
3	Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. <i>Leukemia</i> , 2016, 30, 2019-2025.	7.2	48
4	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. <i>Future Oncology</i> , 2015, 11, 1895-1903.	2.4	34
5	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2015, 100, 1451-1459.	3.5	34
6	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 253-260.	2.2	19
7	New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. <i>Leukemia and Lymphoma</i> , 2019, 60, 649-657.	1.3	15
8	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	3.5	12
9	Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. <i>Blood</i> , 2015, 126, 2934-2934.	1.4	6
10	Treatment-specific evaluation of the modified Glasgow Prognostic Score in patients with advanced cutaneous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e879-e883.	2.4	3
11	Case Report: Large Granular Lymphocyte Leukemia (LGLL) – A Case Series of Challenging Presentations. <i>Frontiers in Oncology</i> , 2021, 11, 775313.	2.8	3
12	Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamide Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2011, 118, 2863-2863.	1.4	2
13	Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. <i>HemaSphere</i> , 2021, 5, e664.	2.7	0